270 related articles for article (PubMed ID: 19082507)
1. VLHL plasminogen activator inhibitor spontaneously reactivates from the latent to active form.
Jankun J; Aleem AM; Selman SH; Basrur V; Skrzypczak-Jankun E
Int J Mol Med; 2009 Jan; 23(1):57-63. PubMed ID: 19082507
[TBL] [Abstract][Full Text] [Related]
2. Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries.
Stoop AA; Eldering E; Dafforn TR; Read RJ; Pannekoek H
J Mol Biol; 2001 Jan; 305(4):773-83. PubMed ID: 11162091
[TBL] [Abstract][Full Text] [Related]
3. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen activator inhibitor-1 is locked in active conformation and polymerizes upon binding ligands neutralizing its activity.
Jankun J; Specht Z; Szkudlarek M; Greenfield R; Gaikwad B; Trifonov L; Vaugeois J; Aleem AM; Basrur V; Selman SH; Zavodszky MI; Skrzypczak-Jankun E
Int J Mol Med; 2006 Mar; 17(3):437-47. PubMed ID: 16465390
[TBL] [Abstract][Full Text] [Related]
5. Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation.
Nar H; Bauer M; Stassen JM; Lang D; Gils A; Declerck PJ
J Mol Biol; 2000 Mar; 297(3):683-95. PubMed ID: 10731421
[TBL] [Abstract][Full Text] [Related]
6. Distal hinge of plasminogen activator inhibitor-1 involves its latency transition and specificities toward serine proteases.
Wang Q; Shaltiel S
BMC Biochem; 2003 Jul; 4():5. PubMed ID: 12848892
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of the proteinase specificity in wild-type and stabilized plasminogen activator inhibitor-1: evidence for contribution of intramolecular flexibility.
De Taeye B; Gils A; Vleugels N; Rabijns A; Declerck PJ
Biochem Biophys Res Commun; 2004 Aug; 321(3):746-51. PubMed ID: 15358169
[TBL] [Abstract][Full Text] [Related]
8. Remarkable extension of PAI-1 half-life surprisingly brings no changes to its structure.
Jankun J; Yang J; Zheng H; Han FQ; Al-Senaidy A; Skrzypczak-Jankun E
Int J Mol Med; 2012 Jan; 29(1):61-4. PubMed ID: 21947232
[TBL] [Abstract][Full Text] [Related]
9. Effect of stabilizing versus destabilizing interactions on plasminogen activator inhibitor-1.
Vleugels N; Leys J; Knockaert I; Declerck PJ
J Pharm Belg; 2000; 55(2):57-8. PubMed ID: 10842928
[TBL] [Abstract][Full Text] [Related]
10. Kinetically controlled folding of the serpin plasminogen activator inhibitor 1.
Wang Z; Mottonen J; Goldsmith EJ
Biochemistry; 1996 Dec; 35(51):16443-8. PubMed ID: 8987976
[TBL] [Abstract][Full Text] [Related]
11. A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis.
Chorostowska-Wynimko J; Swiercz R; Skrzypczak-Jankun E; Wojtowicz A; Selman SH; Jankun J
Mol Cancer Ther; 2003 Jan; 2(1):19-28. PubMed ID: 12533669
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen activator inhibitor-1 polymers, induced by inactivating amphipathic organochemical ligands.
Pedersen KE; Einholm AP; Christensen A; Schack L; Wind T; Kenney JM; Andreasen PA
Biochem J; 2003 Jun; 372(Pt 3):747-55. PubMed ID: 12656676
[TBL] [Abstract][Full Text] [Related]
13. A peptide mimicking the C-terminal part of the reactive center loop induces the transition to the latent form of plasminogen activator inhibitor type-1.
D'Amico S; Martial JA; Struman I
FEBS Lett; 2012 Mar; 586(6):686-92. PubMed ID: 22449964
[TBL] [Abstract][Full Text] [Related]
14. The Bbeta-sheet in the PAI-1 molecule plays an important role for its stability.
Sui GC; Wiman B
Thromb Haemost; 2000 Jun; 83(6):896-901. PubMed ID: 10896245
[TBL] [Abstract][Full Text] [Related]
15. Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop.
Gils A; Knockaert I; Declerck PJ
Biochemistry; 1996 Jun; 35(23):7474-81. PubMed ID: 8652525
[TBL] [Abstract][Full Text] [Related]
16. Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis.
Björquist P; Ehnebom J; Inghardt T; Hansson L; Lindberg M; Linschoten M; Strömqvist M; Deinum J
Biochemistry; 1998 Feb; 37(5):1227-34. PubMed ID: 9477948
[TBL] [Abstract][Full Text] [Related]
17. Specific interactions of serpins in their native forms attenuate their conformational transitions.
Na YR; Im H
Protein Sci; 2007 Aug; 16(8):1659-66. PubMed ID: 17600149
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory mechanism of serpins: loop insertion forces acylation of plasminogen activator by plasminogen activator inhibitor-1.
Kvassman JO; Verhamme I; Shore JD
Biochemistry; 1998 Nov; 37(44):15491-502. PubMed ID: 9799512
[TBL] [Abstract][Full Text] [Related]
19. Analysis of serpin inhibitory function by mutagenesis of ovalbumin and generation of chimeric ovalbumin/PAI-2 fusion proteins.
McCarthy BJ; Worrall DM
J Mol Biol; 1997 Apr; 267(3):561-9. PubMed ID: 9126838
[TBL] [Abstract][Full Text] [Related]
20. PAI-1 induces cell detachment, downregulates nucleophosmin (B23) and fortilin (TCTP) in LnCAP prostate cancer cells.
Jankun J; Aleem AM; Specht Z; Keck RW; Lysiak-Szydlowska W; Selman SH; Skrzypczak-Jankun E
Int J Mol Med; 2007 Jul; 20(1):11-20. PubMed ID: 17549383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]